SA47 Clinical Effectiveness of Osimertinib in Non-Small Cell Lung Cancer Patients With EGFR Mutation Between Plasma and Tissue Re-Biopsy: A Systematic Review and Meta-Analysis of Real-World Evidence

Wc Wu,Lc Hsu,Kc Chang,Sc Shao,Hy Chen

doi:10.1016/j.jval.2022.09.2441

SA47 Clinical Effectiveness of Osimertinib in Non-Small Cell Lung Cancer Patients With EGFR Mutation Between Plasma and Tissue Re-Biopsy: A Systematic Review and Meta-Analysis of Real-World Evidence

Wc Wu, Lc Hsu + Show 3 more

Open Access

https://doi.org/10.1016/j.jval.2022.09.2441

Copy DOI

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research	Publication Date: Dec 1, 2022
License type: publisher-specific-oa

Affiliation: Linkou Chang Gung Memorial Hospital, Chang Gung Memorial Hospital, Keelung Chang Gung Memorial Hospital

#Meta-analysis Of Real-world Evidence #Tissue Re-biopsy + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

SA47 Clinical Effectiveness of Osimertinib in Non-Small Cell Lung Cancer Patients With EGFR Mutation Between Plasma and Tissue Re-Biopsy: A Systematic Review and Meta-Analysis of Real-World Evidence

Full Text